End of Content.
Non-Invasive Prenatal Screening (NIPS)
NIPS – Non-Invasive Prenatal Screening is an advanced and simple blood test used in the detection of fetal chromosomal aneuploidies that analyzes cell-free fetal DNA in the blood of a pregnant woman. Aneuploidy is the leading known genetic cause of miscarriages and congenital birth defects. The International Society for Prenatal Diagnosis (ISPD), The National Society of Genetic Counsellers (NSGC), The American College of Obstetricians and Gynaecologists (ACOG) and The Society for Maternal Fetal Medicine (SMFM) have all agreed that NIPS is a safe and effective screening test.
As per the recent ACOG guidelines released in August 2020, NIPS is now recommended for screening of all pregnancies irrespective of risk for foetal aneuploidy in high-risk pregnancies.
Recommended for
- Incase of high-risk maternal marker screening
- Abnormal ultra sonography
- History of miscarriages or infertility
- If the couple have a child with a chromosomal abnormality
- Family history of chromosomal abnormalities
Notification to the consultant following receipt of the sample in the amount of cell-free fetal DNA (cffDNA) is too low
Given the high sensitivity of NIPS, patients with negative NIPS results should be counselled that the chance of aneuploidy for the chromosomes tested is low. However, a negative result does not completely rule out the possibility of trisomies 21, 18 and 13. NIPS results should be used in the context of all relevant clinica information.
For any further information, please fill in the form below and we will call you back shortly:
Frequently asked questions
Find answers to your lab service questions in our FAQ section
Orbito Asia offers Non-Invasive Prenatal Screening (NIPS), a cutting-edge genetic testing method that analyzes cell-free fetal DNA circulating in the mother's blood to assess the risk of certain chromosomal abnormalities in the unborn baby.
Orbito Asia's NIPS service screens for common chromosomal abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and certain sex chromosome abnormalities.
Orbito Asia's NIPS has a high accuracy rate, with results providing a reliable assessment of the risk for chromosomal abnormalities. However, it is important to note that no test is 100% accurate, and a diagnostic test may be recommended for confirmation in cases of high risk.
To schedule an NIPS test with Orbito Asia, please contact our customer service team at [insert contact information]. They will guide you through the process, answer any additional questions, and assist with appointment scheduling.
NIPS is non-invasive and poses no risk to the fetus. It provides highly accurate results for common chromosomal conditions such as Down syndrome, Edwards syndrome, and Patau syndrome without the need for invasive procedures like amniocentesis.
NIPS is typically performed after 9 weeks of pregnancy. It is advisable to consult with your healthcare provider to determine the optimal time for testing based on your individual circumstances.
Typically, results are available within 7-10 business days after the sample is received by the laboratory. However, processing times may vary.
If your NIPS results indicate a higher risk for a chromosomal abnormality, further diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS), may be recommended. Your healthcare provider will discuss the results with you and provide guidance on the next steps.
